Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
An update from Esperion (ESPR) is now available.
Esperion Therapeutics, Inc. struck a deal on June 27, 2024, selling a portion of its Bempedoic Acid net sales royalties for over $304 million to OCM IP Healthcare Portfolio LP. This transaction allows the purchaser to fully recoup 1.7 times the purchase price before the royalties revert back to Esperion. Additionally, the company cleared its financial slate by repaying $343.75 million in cash to settle all outstanding Revenue Interests and related obligations, resulting in the termination of the prior agreement and release of all associated security interests.
For detailed information about ESPR stock, go to TipRanks’ Stock Analysis page.
